Quantum BioPharma Ltd. (QNTM) - Digitally Engineered Life Sciences Company FAQ

What is Quantum BioPharma Ltd. and what does it do?

Quantum BioPharma (NASDAQ: QNTM) (CSE: QNTM) is a biopharmaceutical company building a portfolio of innovative assets and biotech solutions for treating challenging neurodegenerative and metabolic disorders and alcohol misuse disorders, with drug candidates in different stages of development.

What is Quantum BioPharma’s flagship neuroprotective program?

The company’s flagship neuroprotective program is Lucid-MS, developed with Massachusetts General Hospital to address demyelination in multiple sclerosis, which has been shown to prevent and reverse myelin degradation in preclinical models.

How is Quantum BioPharma redefining the life sciences industry?

The company is transforming biotechnology through a digitally integrated model that merges clinical innovation, consumer health commercialization, and market infrastructure modernization, positioning itself as a prototype for digitally engineered life sciences enterprises.

What consumer health products does Quantum BioPharma have?

Quantum BioPharma invented unbuzzd™ beverage and spun out its OTC version to Unbuzzd Wellness Inc., where Quantum retains 20.11% ownership and receives royalty payments of 7% of sales until payments total $250 million, then 3% in perpetuity.

What trading platforms is Quantum BioPharma listed on?

Quantum BioPharma has a dual listing on NASDAQ (QNTM), CSE (QNTM), and is also positioned on Upstream, making it a next-generation public issuer that unites science, transparency, and capital efficiency.

What rights does Quantum BioPharma retain for pharmaceutical development?

Quantum BioPharma retains 100% of the rights to develop similar products or alternative formulations specifically for pharmaceutical and medical uses, separate from the consumer OTC version of unbuzzd™.

What other business activities does Quantum BioPharma engage in?

Through its wholly owned subsidiary FSD Strategic Investments Inc., the company maintains a portfolio of strategic investments representing loans secured by residential or commercial property.

Where can investors find the latest news and updates about Quantum BioPharma?

The latest news and updates relating to QNTM are available in the company’s newsroom at https://ibn.fm/QNTM.

What makes Quantum BioPharma’s growth model unique?

The company employs a multi-vertical growth model that combines traditional biotech R&D with scalable, data-driven operations, consumer health commercialization, and advanced trading technologies, creating a digitally engineered approach to life sciences.

What is the significance of Quantum BioPharma’s partnership with Massachusetts General Hospital?

The partnership with Massachusetts General Hospital for developing Lucid-MS demonstrates the company’s commitment to scientific innovation and collaboration with leading medical institutions to address serious neurological conditions like multiple sclerosis.